Back to Newsroom
Back to Newsroom

Advanced Cell Technology Fills New Position of Chief Commercial Officer

Tuesday, 21 October 2014 06:10 AM

Topic:

 

Advanced Cell Technology Inc. (OTCQB: ACTC), a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology, stock volume was low Oct. 20, with just 83,424 shares changing hands, a quarter of its average 30-day volume of 320,687 shares.

The slowdown comes the same day the company announced the appointment of LeRoux Jooste to the newly created position of Senior Vice President of Business Development and Chief Commercial Officer.

LeRoux has a global track record of building commercial capability and proven success in launching blockbuster products in the USA and Europe. LeRoux joins ACT from Antares Pharma Inc. (NASDAQ: ATRS), where he served as Senior Vice President and General Manager, Pharmaceuticals since May 2012.

Prior to joining Antares, LeRoux was Vice President Commercial Assessment and Product Planning at Cephalon. Earlier in his career he held senior level positions at Nabi Biopharmaceuticals, Aton Pharma, Wyeth and Eli Lilly. LeRoux graduated from Pharmacy School in Pretoria, South Africa and received his Bachelor of Commerce from the University of South Africa.

On Oct. 20, ACTC's share price closed at $7.08, down 10 cents from the previous day's close $7.18.

Find out what could be the best investor's move when it comes to AMBS by getting the complete report here or by cutting and pasting the following link in your Web browser:

www.sixfigurestockpicks.com

 

ChromaDex Corp. Stock Volume Down

ChromaDex Corp.'s (OTCQB: CDXC) stock volume was also low Oct. 20, with just 43,540 shares changing hands, about half its 30-day average volume of 95,872.

This comes only a week after the news the Irvine, Calif.-based ingredient technology company had launched a new anti-aging supplement.

According to Chroma the new product named Dex NAD+ Cell Regenerator(TM) is an innovative nutritional supplement that boosts vitality and supports healthy aging. NAD+ Cell Regenerator(TM) features the ingredient NIAGEN(TM) from ChromaDex.

On Oct. 20, the share price of CDXC closed at $1.02, unchanged from previous day's close.

Find out what could be the best investor's move when it comes to ONCS by getting the complete report here or by cutting and pasting the following link in your Web browser:

www.sixfigurestockpicks.com

 

Creative Edge Nutrition Stock Rises 12.89% despite Potential Legal Battle

On Oct. 20, Creative Edge Nutrition Inc.'s (OTCPINK: FITX) share price closed at 0.0429 cents, up 0.0049, or 12.89%, from the previous day's close of 0.038 on below average volume of 10 million shares.

Creative Edge experienced this slight uptick in share value despite the recent news that the Lakewood Town Council and some residents of the Ontario municipality are strongly opposing the operation the company in their town has prompted the medical marijuana company to lawyer up in an attempt to get its plans back on track.

On Oct. 2 Creative Edge announced that it has retained the leading Ukrainian National law firm Vasil Kisil & Partners as its Ukrainian corporate counsel. But whether this law firm are miracle workers remains to be seen. Some industry observers say the law firm has its work cut out for it.

The latest negative development in this major setback for the would-be medical marijuana facility was Creative Edge's admission in a Sept. 29 press release that the Town Council has already passed a resolution to issue a letter to "Health Canada asking it to hold off on issuing a license for our facility."

If this is the case, it could end up being a death blow to the company's chances of ever being granted a license to sell medical marijuana in Canada.

Needs to be Resolved

While Creative Edge is crying foul and licking its wounds, some industry observers wonder how its top executives didn't see this citizen revolt coming – and why they didn't have a plan B in place, in case it did.

It should come as no surprise that some residents of small and medium-sized towns still believe that any kind of marijuana business carries a stigma that might hurt its reputation. In fact, it is common for any kind of development – even shopping malls -- to meet stiff resistance from those who live in the proximity where the new project is being proposed.

Find out what could be the best investor's move when it comes to FITX by getting the complete report here or by cutting and pasting the following link in your Web browser:

www.sixfigurestockpicks.com

 

Nuvilex's Contracts with University of Veterinary for New Studies

On Oct. 20, Nuvilex Inc. (OTCQB: NVLX) announced that it has entered into a Collaborative Research Agreement (CRA) with the University of Veterinary Medicine in Vienna, Austria (University).

The CRA calls for the University to perform "in vitro" and animal studies that use the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology to develop a new treatment for insulin-dependent diabetes. Nuvilex has been granted worldwide, royalty-free, rights to use the results of the research conducted by the University for all commercial purposes.

Among the initial studies to be performed by the University will be the testing of an insulin-producing cell line developed by the University of Technology, Sydney, to determine whether that cell line has the potential to form tumors when implanted into animals; i.e. whether those cells are "tumorigenic." If this cell line proves to be non-tumorigenic, then cells from this cell line will be encapsulated using the Cell-in-a-Box(R) technology.

Additional animal studies will be carried out at the University to determine if these encapsulated cells can act as a form of "bio-artificial pancreas" in animal model systems. Dr. Günzburg and his associates have already worked with these insulin-producing cells in an in vitro setting and have confirmed that they can produce insulin in direct response to the levels of glucose (sugar) to which they are exposed.

NVLX's share price closed at 25 cents, up 1 cent from its close of 24 cents the previous day, on flat volume of 1.9 million shares.

Find out what could be the best investor's move when it comes to NVLX by getting the complete report here or by cutting and pasting the following link in your Web browser:

www.sixfigurestockpicks.com

 

ABOUT US:

www.sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.

www.sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

www.sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the www.sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: www.sixfigurestockpicks.com

Disclosure

www.sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.

Topic:
Back to newsroom
Back to Newsroom
Share by: